Breaking News Instant updates and real-time market news.

ICPT

Intercept

$16.47 /

-0.56 (-3.29%)

07:57
09/30/22
09/30
07:57
09/30/22
07:57

Intercept says REVERSE Phase 3 study did not meet primary endpoint

Intercept Pharmaceuticals announced that REVERSE, a Phase 3 study evaluating the safety and efficacy of OCA in patients with compensated cirrhosis due to nonalcoholic steatohepatitis, did not meet its primary endpoint of a greater than or equal to 1-stage histological improvement in fibrosis with no worsening of NASH following up to 18 months of therapy. No new safety signals for OCA were observed in this population of patients with cirrhosis. REVERSE is one of Intercept's two Phase 3 studies evaluating different populations in NASH. The Company's planned NDA for its lead indication of liver fibrosis due to NASH will be supported by positive Phase 3 data from the REGENERATE study and is unaffected by the efficacy results of REVERSE. The Company is on track to resubmit its NDA in liver fibrosis due to NASH by the end of the year. In the REVERSE study of 919 randomized subjects with compensated cirrhosis due to NASH, 11.1% of subjects who were randomized to receive once-daily oral OCA 10 mg and 11.9% of subjects who were randomized to receive OCA 10 mg titrated to 25 mg after three months achieved a greater than or equal to1-stage improvement in fibrosis with no worsening of NASH after up to 18 months of treatment, compared with 9.9% of subjects who received placebo. Though the REVERSE study did not succeed on the histological evaluation of the primary endpoint, a positive impact on liver stiffness as defined by transient elastography was noted in both OCA 10 mg and OCA 10-to-25 mg arms.Safety was evaluated in 916 subjects who took at least one dose of study drug. Treatment-emergent adverse events, treatment-emergent serious adverse events and deaths were balanced across all treatment groups in REVERSE. The most common TEAE was pruritus and pruritus was the most common reason for treatment discontinuation. Serious gallbladder-related events were balanced across arms. Consistent with the known mechanism of action of FXR-agonists, the OCA 10-to-25 mg arm had a higher incidence of gallstones. Independent experts reviewed certain categories of safety events to provide a blinded adjudication as specifically requested by FDA. These included events pertaining to hepatic safety, cardiovascular safety and renal safety. There was a numerical increase in the number of adjudicated hepatic safety events for the OCA-treated arms; most were mild in severity and related to biochemical changes. There were no severe or fatal adjudicated hepatic safety events in any treatment arm. Frequency of adjudicated kidney events and adjudicated major cardiac adverse events were balanced across treatment groups. Intercept is grateful to the patients and clinicians who participated in the REVERSE trial. The Company will continue to work with REVERSE investigators to analyze the data from both the double-blind portion of the study as well as the open-label extension phase of REVERSE, and plans to share these data at an upcoming scientific forum.

OTHER BREAKING NEWS FROM THE FLY

Options
Unusually active option classes on open February 8th » 09:40
02/08/23
02/08
09:40
02/08/23
09:40
UBER

Uber

$34.95 /

+0.04 (+0.11%)

, GOOGL

Alphabet

$107.69 /

-0.05 (-0.05%)

, CVS

CVS Health

$86.02 /

+ (+0.00%)

, GOOG

Alphabet

$108.01 /

+ (+0.00%)

, MSFT

Microsoft

$267.58 /

+ (+0.00%)

, BBAI

BigBear.ai

$4.94 /

+ (+0.00%)

, AI

C3.ai

$24.53 /

+ (+0.00%)

, BIDU

Baidu

$160.21 /

+ (+0.00%)

, LQD

iShares iBoxx $ Investment Grade Corporate Bond

$109.34 /

+ (+0.00%)

, ATVI

Activision Blizzard

$75.61 /

+ (+0.00%)

Unusual total active…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
UBER Uber
$34.95 /

+0.04 (+0.11%)

GOOGL Alphabet
$107.69 /

-0.05 (-0.05%)

CVS CVS Health
$86.02 /

+ (+0.00%)

GOOG Alphabet
$108.01 /

+ (+0.00%)

MSFT Microsoft
$267.58 /

+ (+0.00%)

BBAI BigBear.ai
$4.94 /

+ (+0.00%)

AI C3.ai
$24.53 /

+ (+0.00%)

BIDU Baidu
$160.21 /

+ (+0.00%)

LQD iShares iBoxx $ Investment Grade Corporate Bond
$109.34 /

+ (+0.00%)

ATVI Activision Blizzard
$75.61 /

+ (+0.00%)

UBER Uber
$34.95 /

+0.04 (+0.11%)

01/31/23 Mizuho
Mizuho 'constructive' on Uber shares into Q4 results
01/30/23 MoffettNathanson
Uber initiated with an Outperform at MoffettNathanson
01/26/23 Cowen
Uber price target lowered to $66 from $70 at Cowen
01/24/23 KeyBanc
KeyBanc upgrades Lyft on 'meaningful opportunity' for EBITDA lift
GOOGL Alphabet
$107.69 /

-0.05 (-0.05%)

08:20 Today DA Davidson
Microsoft price target raised to $325 from $280 at DA Davidson
07:53 Today Loop Capital
Alphabet price target raised to $125 from $120 at Loop Capital
02/07/23 Wedbush
Microsoft set to unveil ChatGPT partnership as AI arms race begins, says Wedbush
02/03/23 Truist
Alphabet price target lowered to $120 from $130 at Truist
CVS CVS Health
$86.02 /

+ (+0.00%)

08:07 Today Piper Sandler
Oak Street Health downgraded to Neutral from Overweight at Piper Sandler
07:36 Today Stifel
Oak Street Health downgraded to Hold from Buy at Stifel
02/07/23 Stifel
Oak Street Health price target raised to $39 from $35 at Stifel
02/07/23 Piper Sandler
Oak Street 'particularly attractive' in current environment, says Piper Sandler
GOOG Alphabet
$108.01 /

+ (+0.00%)

02/07/23 Wedbush
Microsoft set to unveil ChatGPT partnership as AI arms race begins, says Wedbush
02/03/23 JPMorgan
Alphabet price target raised to $118 from $115 at JPMorgan
02/03/23 Credit Suisse
Alphabet price target lowered to $136 from $145 at Credit Suisse
02/03/23 Morgan Stanley
Alphabet price target raised to $135 from $125 at Morgan Stanley
MSFT Microsoft
$267.58 /

+ (+0.00%)

08:38 Today Morgan Stanley
Microsoft 'coming out swinging' in ramping AI/ML tech cycle, says Morgan Stanley
08:20 Today DA Davidson
Microsoft price target raised to $325 from $280 at DA Davidson
07:31 Today Wells Fargo
Wells says OpenAI investments place Microsoft 'front & center' of AI hype cycle
06:42 Today Mizuho
Microsoft price target raised to $300 from $280 at Mizuho
BBAI BigBear.ai
$4.94 /

+ (+0.00%)

08/10/22 Oppenheimer
Oppenheimer downgrades BigBear.ai to Perform following 'disappointing' quarter
08/10/22 Oppenheimer
BigBear.ai downgraded to Perform from Outperform at Oppenheimer
03/28/22 Oppenheimer
BigBear.ai initiated with an Outperform at Oppenheimer
02/09/22 William Blair
BigBear.ai initiated with a Market Perform at William Blair
AI C3.ai
$24.53 /

+ (+0.00%)

02/02/23 DA Davidson
C3.ai initiated with a Buy at DA Davidson
12/08/22 Morgan Stanley
C3.ai price target lowered to $12 from $13 at Morgan Stanley
12/08/22 Piper Sandler
C3.ai price target lowered to $13 from $14 at Piper Sandler
12/08/22 Deutsche Bank
C3.ai price target lowered to $11 from $13 at Deutsche Bank
BIDU Baidu
$160.21 /

+ (+0.00%)

01/31/23 Citi
Baidu price target raised to $176 from $166 at Citi
01/20/23 UBS
Baidu price target lowered to $182 from $185 at UBS
01/17/23 Jefferies
Baidu price target lowered to $210 from $217 at Jefferies
12/14/22 Susquehanna
Baidu price target lowered to $150 from $195 at Susquehanna
LQD iShares iBoxx $ Investment Grade Corporate Bond
$109.34 /

+ (+0.00%)

ATVI Activision Blizzard
$75.61 /

+ (+0.00%)

01/27/23 Wedbush
Activision Blizzard assumed with an Outperform at Wedbush
12/22/22 Needham
Netflix 2023 estimates cut at Needham
12/06/22 Edward Jones
Activision Blizzard upgraded to Buy from Hold at Edward Jones
12/01/22 Wedbush
Activision Blizzard added to Best Ideas List at Wedbush
UBER Uber
$34.95 /

+0.04 (+0.11%)

GOOGL Alphabet
$107.69 /

-0.05 (-0.05%)

CVS CVS Health
$86.02 /

+ (+0.00%)

GOOG Alphabet
$108.01 /

+ (+0.00%)

MSFT Microsoft
$267.58 /

+ (+0.00%)

BBAI BigBear.ai
$4.94 /

+ (+0.00%)

AI C3.ai
$24.53 /

+ (+0.00%)

BIDU Baidu
$160.21 /

+ (+0.00%)

ATVI Activision Blizzard
$75.61 /

+ (+0.00%)

UBER Uber
$34.95 /

+0.04 (+0.11%)

GOOGL Alphabet
$107.69 /

-0.05 (-0.05%)

CVS CVS Health
$86.02 /

+ (+0.00%)

GOOG Alphabet
$108.01 /

+ (+0.00%)

MSFT Microsoft
$267.58 /

+ (+0.00%)

BIDU Baidu
$160.21 /

+ (+0.00%)

ATVI Activision Blizzard
$75.61 /

+ (+0.00%)

UBER Uber
$34.95 /

+0.04 (+0.11%)

GOOGL Alphabet
$107.69 /

-0.05 (-0.05%)

CVS CVS Health
$86.02 /

+ (+0.00%)

GOOG Alphabet
$108.01 /

+ (+0.00%)

MSFT Microsoft
$267.58 /

+ (+0.00%)

BBAI BigBear.ai
$4.94 /

+ (+0.00%)

AI C3.ai
$24.53 /

+ (+0.00%)

BIDU Baidu
$160.21 /

+ (+0.00%)

ATVI Activision Blizzard
$75.61 /

+ (+0.00%)

UBER Uber
$34.95 /

+0.04 (+0.11%)

GOOGL Alphabet
$107.69 /

-0.05 (-0.05%)

CVS CVS Health
$86.02 /

+ (+0.00%)

GOOG Alphabet
$108.01 /

+ (+0.00%)

MSFT Microsoft
$267.58 /

+ (+0.00%)

BBAI BigBear.ai
$4.94 /

+ (+0.00%)

AI C3.ai
$24.53 /

+ (+0.00%)

BIDU Baidu
$160.21 /

+ (+0.00%)

LQD iShares iBoxx $ Investment Grade Corporate Bond
$109.34 /

+ (+0.00%)

ATVI Activision Blizzard
$75.61 /

+ (+0.00%)

Recommendations
Model N price target raised to $48 from $42 at BTIG » 09:36
02/08/23
02/08
09:36
02/08/23
09:36
MODN

Model N

$40.82 /

+0.555 (+1.38%)

BTIG analyst Matt…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MODN Model N
$40.82 /

+0.555 (+1.38%)

MODN Model N
$40.82 /

+0.555 (+1.38%)

09:06 Today Truist
Model N price target raised to $52 from $45 at Truist
11/09/22 Needham
Model N price target raised to $42 from $34 at Needham
11/09/22 Truist
Model N price target raised to $45 from $35 at Truist
11/09/22 Craig-Hallum
Model N price target raised to $42 from $34 at Craig-Hallum
MODN Model N
$40.82 /

+0.555 (+1.38%)

MODN Model N
$40.82 /

+0.555 (+1.38%)

Recommendations
TransDigm price target raised to $810 from $710 at Truist » 09:34
02/08/23
02/08
09:34
02/08/23
09:34
TDG

TransDigm

$742.31 /

+21.96 (+3.05%)

Truist analyst Michael…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TDG TransDigm
$742.31 /

+21.96 (+3.05%)

TDG TransDigm
$742.31 /

+21.96 (+3.05%)

08:55 Today RBC Capital
TransDigm price target raised to $800 from $750 at RBC Capital
07:43 Today Credit Suisse
TransDigm price target raised to $830 from $765 at Credit Suisse
07:35 Today Cowen
TransDigm price target raised to $830 from $695 at Cowen
07:28 Today Susquehanna
TransDigm price target raised to $750 from $665 at Susquehanna
TDG TransDigm
$742.31 /

+21.96 (+3.05%)

Hot Stocks
Titan Medical to resume trading at 9:50 am ET » 09:34
02/08/23
02/08
09:34
02/08/23
09:34
TMDI

Titan Medical

/

+

Shares of Titan Medical…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TMDI Titan Medical
/

+

TMDI Titan Medical
/

+

03/25/22 Oppenheimer
Titan Medical downgraded to Perform from Outperform at Oppenheimer
03/25/22 Oppenheimer
Titan Medical downgraded to Perform from Outperform at Oppenheimer
TMDI Titan Medical
/

+

Periodicals
General Motors competing for stake in Vale base metals unit, Bloomberg says » 09:31
02/08/23
02/08
09:31
02/08/23
09:31
GM

General Motors

$41.41 /

+0.075 (+0.18%)

, VALE

Vale

$16.96 /

-0.01 (-0.06%)

General Motors (GM) is…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GM General Motors
$41.41 /

+0.075 (+0.18%)

VALE Vale
$16.96 /

-0.01 (-0.06%)

GM General Motors
$41.41 /

+0.075 (+0.18%)

02/02/23 Citi
Citi ups GM target, reiterates as top pick post results
02/01/23 Deutsche Bank
General Motors price target raised to $36 from $33 at Deutsche Bank
02/01/23 Morgan Stanley
General Motors price target raised to $35 from $32 at Morgan Stanley
02/01/23 BofA
General Motors price target lowered to $70 from $80 at BofA
VALE Vale
$16.96 /

-0.01 (-0.06%)

02/06/23 RBC Capital
RBC downgrades Vale, says shares 'moved past fair value'
02/06/23 RBC Capital
Vale downgraded to Sector Perform from Outperform at RBC Capital
12/09/22 Morgan Stanley
Vale upgraded to Overweight from Equal Weight at Morgan Stanley
12/08/22 BMO Capital
Vale price target raised to $20 from $16 at BMO Capital
GM General Motors
$41.41 /

+0.075 (+0.18%)

GM General Motors
$41.41 /

+0.075 (+0.18%)

GM General Motors
$41.41 /

+0.075 (+0.18%)

VALE Vale
$16.96 /

-0.01 (-0.06%)

GM General Motors
$41.41 /

+0.075 (+0.18%)

VALE Vale
$16.96 /

-0.01 (-0.06%)

Recommendations
Malibu Boats price target raised to $72 from $65 at Truist » 09:30
02/08/23
02/08
09:30
02/08/23
09:30
MBUU

Malibu Boats

$63.43 /

+0.85 (+1.36%)

Truist analyst Michael…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MBUU Malibu Boats
$63.43 /

+0.85 (+1.36%)

11/07/22 Raymond James
Malibu Boats price target lowered to $75 from $88 at Raymond James
11/07/22 BMO Capital
Malibu Boats price target lowered to $76 from $94 at BMO Capital
10/25/22 B. Riley
Malibu Boats price target lowered to $74 from $89 at B. Riley
10/05/22 Truist
Malibu Boats price target lowered to $65 from $75 at Truist
MBUU Malibu Boats
$63.43 /

+0.85 (+1.36%)

Recommendations
Fiserv price target raised to $105 from $95 at Truist » 09:27
02/08/23
02/08
09:27
02/08/23
09:27
FISV

Fiserv

$115.29 /

+8.86 (+8.32%)

Truist analyst Andrew…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FISV Fiserv
$115.29 /

+8.86 (+8.32%)

FISV Fiserv
$115.29 /

+8.86 (+8.32%)

08:34 Today Credit Suisse
Fiserv price target raised to $130 from $115 at Credit Suisse
07:35 Today RBC Capital
Fiserv price target raised to $131 from $123 at RBC Capital
07:28 Today Morgan Stanley
Fiserv price target raised to $117 from $107 at Morgan Stanley
07:24 Today Susquehanna
Fiserv price target raised to $140 from $135 at Susquehanna
FISV Fiserv
$115.29 /

+8.86 (+8.32%)

FISV Fiserv
$115.29 /

+8.86 (+8.32%)

FISV Fiserv
$115.29 /

+8.86 (+8.32%)

Hot Stocks
1847 Cabinets intends to file registration statement for IPO » 09:26
02/08/23
02/08
09:26
02/08/23
09:26
EFSH

1847 Holdings

$1.88 /

-0.03 (-1.57%)

1847 Cabinets announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EFSH 1847 Holdings
$1.88 /

-0.03 (-1.57%)

EFSH 1847 Holdings
$1.88 /

-0.03 (-1.57%)

Hot Stocks
374Water, Inc. to conduct field demonstration of AirSCWO system » 09:26
02/08/23
02/08
09:26
02/08/23
09:26
SCWO

374Water, Inc.

$3.22 /

-0.18 (-5.29%)

374Water has partnered…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
    Recommendations
    Aecom price target raised to $102 from $94 at RBC Capital » 09:25
    02/08/23
    02/08
    09:25
    02/08/23
    09:25
    ACM

    Aecom

    $90.63 /

    +2.24 (+2.53%)

    RBC Capital analyst…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    ShowHide Related Items >><<
    ACM Aecom
    $90.63 /

    +2.24 (+2.53%)

    ACM Aecom
    $90.63 /

    +2.24 (+2.53%)

    02/07/23 Baird
    Aecom price target raised to $103 from $90 at Baird
    01/17/23 KeyBanc
    Aecom price target raised to $100 from $91 at KeyBanc
    01/13/23 Barclays
    Aecom price target raised to $94 from $90 at Barclays
    01/12/23 Credit Suisse
    Aecom upgraded to Outperform from Neutral at Credit Suisse
    ACM Aecom
    $90.63 /

    +2.24 (+2.53%)

    ACM Aecom
    $90.63 /

    +2.24 (+2.53%)

    Hot Stocks
    Dori Segal says majority of First Capital REIT board should be replaced » 09:24
    02/08/23
    02/08
    09:24
    02/08/23
    09:24
    FCXXF

    First Capital REIT

    $13.12 /

    -0.1263 (-0.95%)

    Dori Segal, whose family…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    ShowHide Related Items >><<
    FCXXF First Capital REIT
    $13.12 /

    -0.1263 (-0.95%)

    01/30/23 National Bank
    First Capital REIT price target raised to C$18.50 from C$17 at National Bank
    11/03/22 Canaccord
    First Capital REIT price target raised to C$18.50 from C$17.50 at Canaccord
    11/03/22 Scotiabank
    First Capital REIT price target lowered to C$19 from C$19.50 at Scotiabank
    09/19/22 Industrial Alliance
    First Capital REIT initiated with a Buy at Industrial Alliance
    Recommendations
    New Relic price target raised to $65 from $55 at Truist » 09:22
    02/08/23
    02/08
    09:22
    02/08/23
    09:22
    NEWR

    New Relic

    $64.61 /

    +1.21 (+1.91%)

    Truist analyst Joel…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    ShowHide Related Items >><<
    NEWR New Relic
    $64.61 /

    +1.21 (+1.91%)

    NEWR New Relic
    $64.61 /

    +1.21 (+1.91%)

    07:58 Today RBC Capital
    New Relic price target raised to $75 from $55 at RBC Capital
    07:42 Today Credit Suisse
    New Relic price target raised to $90 from $78 at Credit Suisse
    07:39 Today Wedbush
    New Relic price target raised to $75 from $68 at Wedbush
    07:33 Today Morgan Stanley
    New Relic price target raised to $80 from $67 at Morgan Stanley
    NEWR New Relic
    $64.61 /

    +1.21 (+1.91%)

    NEWR New Relic
    $64.61 /

    +1.21 (+1.91%)

    Hot Stocks
    Cassava Sciences provides enrollment update for Phase 3 studies of simufilam » 09:21
    02/08/23
    02/08
    09:21
    02/08/23
    09:21
    SAVA

    Cassava Sciences

    $29.83 /

    +0.23 (+0.78%)

    Cassava Sciences…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    ShowHide Related Items >><<
    SAVA Cassava Sciences
    $29.83 /

    +0.23 (+0.78%)

    SAVA Cassava Sciences
    $29.83 /

    +0.23 (+0.78%)

    01/25/23 B. Riley
    Cassava Sciences price target lowered to $28 from $44 at B. Riley
    01/24/23 H.C. Wainwright
    H.C. Wainwright positive on Cassava data, says buy the selloff
    11/29/22 Univest Securities
    Cassava Sciences price target lowered to $11 from $12 at Univest Securities
    11/16/22 B. Riley
    Cassava Sciences downgraded to Neutral at B. Riley amid limited disclosures
    SAVA Cassava Sciences
    $29.83 /

    +0.23 (+0.78%)

    SAVA Cassava Sciences
    $29.83 /

    +0.23 (+0.78%)

    SAVA Cassava Sciences
    $29.83 /

    +0.23 (+0.78%)

    SAVA Cassava Sciences
    $29.83 /

    +0.23 (+0.78%)

    Hot Stocks
    Titan Medical trading halted, news pending  09:20
    02/08/23
    02/08
    09:20
    02/08/23
    09:20
    TMDI

    Titan Medical

    /

    +

     
    ShowHide Related Items >><<
    TMDI Titan Medical
    /

    +

    TMDI Titan Medical
    /

    +

    03/25/22 Oppenheimer
    Titan Medical downgraded to Perform from Outperform at Oppenheimer
    03/25/22 Oppenheimer
    Titan Medical downgraded to Perform from Outperform at Oppenheimer
    TMDI Titan Medical
    /

    +

    Hot Stocks
    Humana and ChenMed announce five-year network agreement » 09:20
    02/08/23
    02/08
    09:20
    02/08/23
    09:20
    HUM

    Humana

    $481.12 /

    -5.085 (-1.05%)

    ChenMed, a senior-focused…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    ShowHide Related Items >><<
    HUM Humana
    $481.12 /

    -5.085 (-1.05%)

    HUM Humana
    $481.12 /

    -5.085 (-1.05%)

    02/07/23 Truist
    Humana price target lowered to $560 from $580 at Truist
    02/06/23 Cowen
    Humana price target lowered to $581 from $647 at Cowen
    02/06/23 Credit Suisse
    Humana price target lowered to $575 from $635 at Credit Suisse
    02/03/23 Stephens
    Humana price target lowered to $590 from $625 at Stephens
    HUM Humana
    $481.12 /

    -5.085 (-1.05%)

    HUM Humana
    $481.12 /

    -5.085 (-1.05%)

    HUM Humana
    $481.12 /

    -5.085 (-1.05%)

    HUM Humana
    $481.12 /

    -5.085 (-1.05%)

    Recommendations
    Lake Street sees opportunity in 'muted' reaction to S&W Seed pact with Shell » 09:20
    02/08/23
    02/08
    09:20
    02/08/23
    09:20
    SANW

    S&W Seed

    $1.70 /

    +0.16 (+10.39%)

    , SHEL

    Shell

    $59.61 /

    +1.77 (+3.06%)

    Lake Street analyst Ben…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    ShowHide Related Items >><<
    SANW S&W Seed
    $1.70 /

    +0.16 (+10.39%)

    SHEL Shell
    $59.61 /

    +1.77 (+3.06%)

    SANW S&W Seed
    $1.70 /

    +0.16 (+10.39%)

    SHEL Shell
    $59.61 /

    +1.77 (+3.06%)

    01/23/23 Morgan Stanley
    Shell downgraded to Equal Weight from Overweight at Morgan Stanley
    01/18/23 Redburn
    Shell downgraded to Neutral from Buy at Redburn
    01/12/23 Wolfe Research
    Shell downgraded to Peer Perform from Outperform at Wolfe Research
    12/19/22 Piper Sandler
    Shell price target lowered to $70 from $71 at Piper Sandler
    SANW S&W Seed
    $1.70 /

    +0.16 (+10.39%)

    SHEL Shell
    $59.61 /

    +1.77 (+3.06%)

    SHEL Shell
    $59.61 /

    +1.77 (+3.06%)

    SHEL Shell
    $59.61 /

    +1.77 (+3.06%)

    SHEL Shell
    $59.61 /

    +1.77 (+3.06%)

    Hot Stocks
    Titan Medical to prioritize sale of company's assets, layoff 48 employees » 09:19
    02/08/23
    02/08
    09:19
    02/08/23
    09:19
    TMDI

    Titan Medical

    /

    +

    Titan Medical provided an…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    ShowHide Related Items >><<
    TMDI Titan Medical
    /

    +

    TMDI Titan Medical
    /

    +

    03/25/22 Oppenheimer
    Titan Medical downgraded to Perform from Outperform at Oppenheimer
    03/25/22 Oppenheimer
    Titan Medical downgraded to Perform from Outperform at Oppenheimer
    TMDI Titan Medical
    /

    +

    Recommendations
    BP price target raised to 650 GBp from 550 GBp at RBC Capital » 09:18
    02/08/23
    02/08
    09:18
    02/08/23
    09:18
    BP

    BP

    $37.73 /

    +2.91 (+8.36%)

    RBC Capital analyst Biraj…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    ShowHide Related Items >><<
    BP BP
    $37.73 /

    +2.91 (+8.36%)

    BP BP
    $37.73 /

    +2.91 (+8.36%)

    06:25 Today Bernstein
    BP price target raised to $53 from $48 at Bernstein
    02/07/23 TD Securities
    BP upgraded to Buy from Hold at TD Securities
    01/23/23 Morgan Stanley
    BP price target raised to 636 GBp from 603 GBp at Morgan Stanley
    01/19/23 JPMorgan
    BP price target lowered to 540 GBp from 560 GBp at JPMorgan
    BP BP
    $37.73 /

    +2.91 (+8.36%)

    BP BP
    $37.73 /

    +2.91 (+8.36%)

    BP BP
    $37.73 /

    +2.91 (+8.36%)

    BP BP
    $37.73 /

    +2.91 (+8.36%)

    Recommendations
    Inspire Medical price target raised to $305 from $250 at Lake Street » 09:17
    02/08/23
    02/08
    09:17
    02/08/23
    09:17
    INSP

    Inspire Medical

    $249.33 /

    +5.91 (+2.43%)

    Lake Street analyst Frank…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    ShowHide Related Items >><<
    INSP Inspire Medical
    $249.33 /

    +5.91 (+2.43%)

    INSP Inspire Medical
    $249.33 /

    +5.91 (+2.43%)

    07:45 Today Truist
    Inspire Medical price target raised to $330 from $310 at Truist
    04:30 Today Piper Sandler
    Inspire Medical price target raised to $305 from $300 at Piper Sandler
    01/31/23 Truist
    Inspire Medical price target raised to $310 from $308 at Truist
    01/31/23 Lake Street
    CVRx initiated with a Buy at Lake Street
    INSP Inspire Medical
    $249.33 /

    +5.91 (+2.43%)

    • 12
      Aug
    INSP Inspire Medical
    $249.33 /

    +5.91 (+2.43%)

    Hot Stocks
    Avantax appoints Melissa Loner as CCO » 09:16
    02/08/23
    02/08
    09:16
    02/08/23
    09:16
    AVTA

    Avantax

    $29.20 /

    +0.365 (+1.27%)

    Avantax announced the…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    ShowHide Related Items >><<
    AVTA Avantax
    $29.20 /

    +0.365 (+1.27%)

    AVTA Avantax
    $29.20 /

    +0.365 (+1.27%)

    Recommendations
    Catalent price target raised to $85 from $73 at RBC Capital » 09:16
    02/08/23
    02/08
    09:16
    02/08/23
    09:16
    CTLT

    Catalent

    $71.55 /

    +4.545 (+6.78%)

    RBC Capital analyst Sean…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    ShowHide Related Items >><<
    CTLT Catalent
    $71.55 /

    +4.545 (+6.78%)

    CTLT Catalent
    $71.55 /

    +4.545 (+6.78%)

    08:22 Today BofA
    Catalent price target raised to $78 from $60 at BofA
    07:10 Today Baird
    Catalent price target raised to $82 from $75 at Baird
    05:25 Today Barclays
    Catalent price target raised to $82 from $58 at Barclays
    02/06/23 Jefferies
    Jefferies says Catalent could be valued near $93 on average CDMO buyout multiple
    CTLT Catalent
    $71.55 /

    +4.545 (+6.78%)

    CTLT Catalent
    $71.55 /

    +4.545 (+6.78%)

    CTLT Catalent
    $71.55 /

    +4.545 (+6.78%)

    CTLT Catalent
    $71.55 /

    +4.545 (+6.78%)

    Hot Stocks
    NeuroSense receives approval in Germany to enroll patients in Paradigm study » 09:16
    02/08/23
    02/08
    09:16
    02/08/23
    09:16
    NRSN

    NeuroSense

    $1.55 /

    -0.02 (-1.27%)

    NeuroSense Therapeutics…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    ShowHide Related Items >><<
    NRSN NeuroSense
    $1.55 /

    -0.02 (-1.27%)

    Recommendations
    Illumina price target lowered to $235 from $285 at Stifel » 09:15
    02/08/23
    02/08
    09:15
    02/08/23
    09:15
    ILMN

    Illumina

    $215.71 /

    +7.085 (+3.40%)

    Stifel analyst Daniel…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    ShowHide Related Items >><<
    ILMN Illumina
    $215.71 /

    +7.085 (+3.40%)

    ILMN Illumina
    $215.71 /

    +7.085 (+3.40%)

    08:00 Today RBC Capital
    Illumina price target raised to $303 from $284 at RBC Capital
    07:58 Today BofA
    Illumina price target raised to $230 from $210 at BofA
    05:32 Today Barclays
    Illumina price target lowered to $150 from $160 at Barclays
    01/27/23 Piper Sandler
    Illumina price target lowered to $290 from $300 at Piper Sandler
    ILMN Illumina
    $215.71 /

    +7.085 (+3.40%)

    ILMN Illumina
    $215.71 /

    +7.085 (+3.40%)

    ILMN Illumina
    $215.71 /

    +7.085 (+3.40%)

    ILMN Illumina
    $215.71 /

    +7.085 (+3.40%)

    Upgrade
    Guangshen Railway upgraded to Buy from Hold at Jefferies » 09:11
    02/08/23
    02/08
    09:11
    02/08/23
    09:11
    GNGYF

    Guangshen Railway

    /

    +

    Jefferies analyst Hengli…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    Hot Stocks
    EnWave announces partner plans to launch new seafood snack pack in 2023 » 09:10
    02/08/23
    02/08
    09:10
    02/08/23
    09:10
    NWVCF

    EnWave

    /

    +

    EnWave Corporatio…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return tomorrow

    Get Free Trial

    ShowHide Related Items >><<
    NWVCF EnWave
    /

    +

    NWVCF EnWave
    /

    +

    06/01/22 Raymond James
    EnWave downgraded to Market Perform from Outperform at Raymond James
    NWVCF EnWave
    /

    +

    Get Full Fly Access

    Breaking market intelligence sent straight to you
    Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
    Up-to-date information on important industry events
    Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
    News focused on the companies in your portfolio
    Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.